Browse LGALS3

Summary
SymbolLGALS3
Namelectin, galactoside-binding, soluble, 3
Aliases MAC-2; GALIG; galectin 3; CBP35; GAL3; GALBP; MAC2; 35 kDa lectin; IgE-binding protein; MAC-2 antigen; carbo ......
Chromosomal Location14q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm. Nucleus. Secreted. Note=Secreted by a non-classical secretory pathway and associates with the cell surface.
Domain PF00337 Galactoside-binding lectin
Function

Galactose-specific lectin which binds IgE. May mediate with the alpha-3, beta-1 integrin the stimulation by CSPG4 of endothelial cells migration. Together with DMBT1, required for terminal differentiation of columnar epithelial cells during early embryogenesis (By similarity). In the nucleus: acts as a pre-mRNA splicing factor. Involved in acute inflammatory responses including neutrophil activation and adhesion, chemoattraction of monocytes macrophages, opsonization of apoptotic neutrophils, and activation of mast cells.

> Gene Ontology
 
Biological Process GO:0001771 immunological synapse formation
GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002286 T cell activation involved in immune response
GO:0002291 T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell
GO:0002366 leukocyte activation involved in immune response
GO:0002429 immune response-activating cell surface receptor signaling pathway
GO:0002548 monocyte chemotaxis
GO:0002683 negative regulation of immune system process
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002698 negative regulation of immune effector process
GO:0002757 immune response-activating signal transduction
GO:0002764 immune response-regulating signaling pathway
GO:0002768 immune response-regulating cell surface receptor signaling pathway
GO:0006397 mRNA processing
GO:0006816 calcium ion transport
GO:0007159 leukocyte cell-cell adhesion
GO:0007162 negative regulation of cell adhesion
GO:0008037 cell recognition
GO:0008380 RNA splicing
GO:0008625 extrinsic apoptotic signaling pathway via death domain receptors
GO:0009988 cell-cell recognition
GO:0010959 regulation of metal ion transport
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0030100 regulation of endocytosis
GO:0030335 positive regulation of cell migration
GO:0030593 neutrophil chemotaxis
GO:0030595 leukocyte chemotaxis
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0040017 positive regulation of locomotion
GO:0042098 T cell proliferation
GO:0042110 T cell activation
GO:0042129 regulation of T cell proliferation
GO:0043270 positive regulation of ion transport
GO:0045806 negative regulation of endocytosis
GO:0046651 lymphocyte proliferation
GO:0048245 eosinophil chemotaxis
GO:0048246 macrophage chemotaxis
GO:0050670 regulation of lymphocyte proliferation
GO:0050777 negative regulation of immune response
GO:0050851 antigen receptor-mediated signaling pathway
GO:0050852 T cell receptor signaling pathway
GO:0050854 regulation of antigen receptor-mediated signaling pathway
GO:0050856 regulation of T cell receptor signaling pathway
GO:0050858 negative regulation of antigen receptor-mediated signaling pathway
GO:0050860 negative regulation of T cell receptor signaling pathway
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050868 negative regulation of T cell activation
GO:0050900 leukocyte migration
GO:0050918 positive chemotaxis
GO:0051051 negative regulation of transport
GO:0051249 regulation of lymphocyte activation
GO:0051250 negative regulation of lymphocyte activation
GO:0051272 positive regulation of cellular component movement
GO:0051924 regulation of calcium ion transport
GO:0051928 positive regulation of calcium ion transport
GO:0060326 cell chemotaxis
GO:0060627 regulation of vesicle-mediated transport
GO:0070227 lymphocyte apoptotic process
GO:0070228 regulation of lymphocyte apoptotic process
GO:0070231 T cell apoptotic process
GO:0070232 regulation of T cell apoptotic process
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070509 calcium ion import
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070838 divalent metal ion transport
GO:0071593 lymphocyte aggregation
GO:0071621 granulocyte chemotaxis
GO:0071674 mononuclear cell migration
GO:0071675 regulation of mononuclear cell migration
GO:0071677 positive regulation of mononuclear cell migration
GO:0071887 leukocyte apoptotic process
GO:0072511 divalent inorganic cation transport
GO:0072677 eosinophil migration
GO:0090279 regulation of calcium ion import
GO:0090280 positive regulation of calcium ion import
GO:0097191 extrinsic apoptotic signaling pathway
GO:0097529 myeloid leukocyte migration
GO:0097530 granulocyte migration
GO:1902041 regulation of extrinsic apoptotic signaling pathway via death domain receptors
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903038 negative regulation of leukocyte cell-cell adhesion
GO:1990266 neutrophil migration
GO:2000106 regulation of leukocyte apoptotic process
GO:2000147 positive regulation of cell motility
GO:2000520 regulation of immunological synapse formation
GO:2000521 negative regulation of immunological synapse formation
GO:2001188 regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell
GO:2001189 negative regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001236 regulation of extrinsic apoptotic signaling pathway
GO:2001237 negative regulation of extrinsic apoptotic signaling pathway
Molecular Function GO:0019863 IgE binding
GO:0019865 immunoglobulin binding
GO:0030246 carbohydrate binding
GO:0042056 chemoattractant activity
GO:0043236 laminin binding
GO:0050840 extracellular matrix binding
Cellular Component GO:0001772 immunological synapse
GO:0005681 spliceosomal complex
GO:0005743 mitochondrial inner membrane
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-879415: Advanced glycosylation endproduct receptor signaling
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-6798695: Neutrophil degranulation
Summary
SymbolLGALS3
Namelectin, galactoside-binding, soluble, 3
Aliases MAC-2; GALIG; galectin 3; CBP35; GAL3; GALBP; MAC2; 35 kDa lectin; IgE-binding protein; MAC-2 antigen; carbo ......
Chromosomal Location14q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LGALS3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between LGALS3 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25691328Malignant Neoplasms of the Mouse Mammary GlandInhibit immunity (T cell function)Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells.
23479624Prostate CarcinomaInhibit immunityHere, we show that a β-galactoside-binding lectin [galectin-3 (gal3)] that recognizes the Thomsen-Friedenreich disaccharide (TFD, Galβ1,3GalNAc) present on the surface of most cancer cells is involved in promoting angiogenesis, tumor-endothelial cell adhesion, and metastasis of prostate cancer cells, as well as evading immune surveillance through killing of activated T cells.
21712812Bladder CarcinomaInhibit immunityEngagement of an NK-activating receptor, NKG2D, by its tumour-associated ligand, Major histocompatibility complex class I-related chain A (MICA), is critical to tumour rejection by NK cells. In C2GnT-expressing bladder tumour cells, poly-N-acetyllactosamine was present on core2 O-glycans on MICA, and galectin-3 bound the NKG2D-binding site of MICA through this poly-N-acetyllactosamine. Galectin-3 reduced the affinity of MICA for NKG2D, thereby severely impairing NK cell activation and silencing the NK cells.
18757439Melanoma; Colon CarcinomaInhibit immunityT-cell activation induced by Gal-3 resulted in T-cell apoptosis. We showed that a high level of expression of Gal-3 promoted tumor growth in vitro and in vivo. Using a mouse tumor model, we showed that delivery of high doses of Gal-3 inhibited tumor-reactive T cells and promoted tumor growth in mice receiving tumor-reactive CD8(+) T cells.
Summary
SymbolLGALS3
Namelectin, galactoside-binding, soluble, 3
Aliases MAC-2; GALIG; galectin 3; CBP35; GAL3; GALBP; MAC2; 35 kDa lectin; IgE-binding protein; MAC-2 antigen; carbo ......
Chromosomal Location14q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LGALS3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLGALS3
Namelectin, galactoside-binding, soluble, 3
Aliases MAC-2; GALIG; galectin 3; CBP35; GAL3; GALBP; MAC2; 35 kDa lectin; IgE-binding protein; MAC-2 antigen; carbo ......
Chromosomal Location14q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LGALS3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1090.821
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.2320.956
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0330.991
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5110.263
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0440.983
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.1080.686
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.020.975
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.2270.922
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3140.904
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2440.908
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4340.901
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0170.88
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LGALS3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLGALS3
Namelectin, galactoside-binding, soluble, 3
Aliases MAC-2; GALIG; galectin 3; CBP35; GAL3; GALBP; MAC2; 35 kDa lectin; IgE-binding protein; MAC-2 antigen; carbo ......
Chromosomal Location14q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LGALS3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLGALS3
Namelectin, galactoside-binding, soluble, 3
Aliases MAC-2; GALIG; galectin 3; CBP35; GAL3; GALBP; MAC2; 35 kDa lectin; IgE-binding protein; MAC-2 antigen; carbo ......
Chromosomal Location14q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LGALS3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LGALS3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLGALS3
Namelectin, galactoside-binding, soluble, 3
Aliases MAC-2; GALIG; galectin 3; CBP35; GAL3; GALBP; MAC2; 35 kDa lectin; IgE-binding protein; MAC-2 antigen; carbo ......
Chromosomal Location14q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LGALS3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLGALS3
Namelectin, galactoside-binding, soluble, 3
Aliases MAC-2; GALIG; galectin 3; CBP35; GAL3; GALBP; MAC2; 35 kDa lectin; IgE-binding protein; MAC-2 antigen; carbo ......
Chromosomal Location14q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LGALS3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLGALS3
Namelectin, galactoside-binding, soluble, 3
Aliases MAC-2; GALIG; galectin 3; CBP35; GAL3; GALBP; MAC2; 35 kDa lectin; IgE-binding protein; MAC-2 antigen; carbo ......
Chromosomal Location14q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LGALS3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLGALS3
Namelectin, galactoside-binding, soluble, 3
Aliases MAC-2; GALIG; galectin 3; CBP35; GAL3; GALBP; MAC2; 35 kDa lectin; IgE-binding protein; MAC-2 antigen; carbo ......
Chromosomal Location14q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LGALS3 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting LGALS3.
ID Name Drug Type Targets #Targets
DB018272,3,5,6-Tetrafluoro-4-Methoxy-BenzamideSmall MoleculeLGALS31
DB04465LactoseSmall MoleculeGLT6D1, GLTP, LGALS33